Latest

19:57
[ JCHX (603979.SH): Board unanimously approves proposal for H-share offering and Main Board listing on HKEX ] On 7 September 2026, JCHX (603979.SH) announced that its board had unanimously approved the proposal for the company's initial public offering of H shares and listing on the Main Board of the HKEX, aimed at enhancing its capital strength and comprehensive competitiveness. The proposal remains subject to consideration by the shareholders' meeting and filing or approval by the CSRC, the HKEX and the SFC of Hong Kong.
Tag： JCHX603979.SHA+HIPO
19:52
[ CM BANK (03968.HK): Assistant general manager Wang Xinghai resigns, effective 7 September 2026 ] On 7 September 2026, CM BANK (03968.HK) announced that assistant general manager Mr. Wang Xinghai had resigned due to work reasons, effective from the same day. He confirmed no disagreement with the board and no unfulfilled public commitments, will no longer hold any position in the company or its controlled subsidiaries after his resignation, and has completed the handover of his duties.
Tag： CM BANK03968.HKresignation
19:50
[ CSPC PHARMA (01093.HK): Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults officially initiated in China ] On 7 September 2026, CSPC PHARMA (01093.HK) voluntarily announced the official initiation of the Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults at the first center in China. SYH2085 is a Class 1 chemical small-molecule inhibitor targeting the PA subunit of the influenza virus RNA polymerase; the group obtained an NMPA Clinical Trial Approval Notice in December 2025, and Phase I data have preliminarily validated its safety and pharmacokinetic/pharmacodynamic profiles, while the multicenter, randomized, double-blind, placebo-controlled Phase II study is now recruiting and screening participants.
Tag： CSPC PHARMA01093.HKClinical Trial
19:48
[ CENTRALCHINA MT (09982.HK): Executive director Liu Lin and company secretary Xie Ziqian resign, company temporarily non-compliant with Listing Rules 3.05 and 3.28 ] On 7 September 2026, CENTRALCHINA MT (09982.HK) announced that executive director Ms. Liu Lin and company secretary and authorized representative Mr. Xie Ziqian had resigned, both effective from the same day. Following Mr. Xie's resignation, the company is temporarily non-compliant with Rules 3.05 and 3.28 of the Listing Rules; the board will identify replacements as soon as possible, with executive director Mr. Wang Kai and external company secretarial service providers and/or legal advisers assisting with compliance matters in the interim.
Tag： CENTRALCHINA MT09982.HKresignation
19:16
[ MICROTECH MED-B (02235.HK): Next-generation CGM AiDEX G9 obtains NMPA registration approval for marketing ] On 7 September 2026, MICROTECH MED-B (02235.HK) voluntarily announced that its next-generation patch-style continuous glucose monitoring system AiDEX G9 had obtained marketing approval from the NMPA, featuring an innovative change in technical architecture and comprehensive upgrades in size, lightweight design and wearing comfort over the first-generation product. Citing the IDF Diabetes Atlas 2025, the announcement noted that approximately 148 million Chinese adults aged 20-79 were living with diabetes in 2024, ranking first globally, with 274 million adults with prediabetes.
Tag： MICROTECH MED-B02235.HKR&D Progress
19:09
[ SBP GROUP (01177.HK): Phase I data of TQC3721 dry powder inhaler (PDE3/4 inhibitor) presented at ERS 2026, showing dose-dependent lung function improvement in COPD ] On 7 September 2026, SBP GROUP (01177.HK) voluntarily announced that TQC3721 dry powder inhaler, a PDE3/4 inhibitor developed by its subsidiary Chia Tai Tianqing, had two Phase I datasets presented at ERS 2026: a dose-ranging study in 72 COPD patients showed dose-dependent improvements in peak FEV1 at Day 9 (from 300.0 mL in the 125 μg group to 497.0 mL in the 1000 μg group), and a proof-of-concept study of the combination with glycopyrronium bromide (40 patients) showed clinically meaningful improvements versus the IND/GLY control, with FEV1 trough improving 203 mL and peak 110 mL from baseline. The nebulized suspension formulation of TQC3721 is in Phase III in China and has received CDE breakthrough therapy designation.
Tag： SBP GROUP01177.HKR&D Progress
19:06
[ TIMES CHINA (01233.HK): Contracted sales of about RMB 205 million in August 2026, cumulative about RMB 2.237 billion in the first eight months ] On 7 September 2026, TIMES CHINA (01233.HK) announced its unaudited operational data for the eight months ended 31 August 2026, recording contracted sales (including contracted sales of joint venture projects) of approximately RMB 205 million with contracted GFA of approximately 16,900 sq.m. in August, and cumulative contracted sales of approximately RMB 2.237 billion with cumulative contracted GFA of approximately 219,700 sq.m. for the eight-month period.
Tag： TIMES CHINA01233.HKBusiness Data
19:03
[ HENGRUI PHARMA (01276.HK): Clinical trials approved for HRS-6209 capsules and HRS-4508 tablets in advanced breast cancer and solid tumors ] On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that it had received NMPA Clinical Trial Approval Notices for HRS-6209 capsules and HRS-4508 tablets, approving an open-label, multicenter Phase Ib/II study of HRS-6209 in combination with other anti-tumor therapies in advanced unresectable or metastatic breast cancer and of HRS-9813 in advanced solid tumors. HRS-6209 is a novel selective CDK4 inhibitor that has advanced into Phase II, and HRS-4508 tablets are a novel selective tyrosine kinase inhibitor; cumulative R&D investment in the two projects amounts to approximately RMB 160.9 million and RMB 96.7 million respectively.
Tag： HENGRUI PHARMA01276.HKClinical Trial
19:00
[ HENGRUI PHARMA (01276.HK): HRS-1597 tablets approved for clinical trial for weight management ] On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Shandong Shengdi Pharmaceutical had received an NMPA Clinical Trial Approval Notice for HRS-1597 tablets, approving clinical trials for the weight management indication. The drug is a Class 1 innovative drug independently developed by the company with no similar drug yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 16.9 million.
Tag： HENGRUI PHARMA01276.HKClinical Trial
18:58
[ HENGRUI PHARMA (01276.HK): SHR-1179 injection approved for clinical trial, targeting weight management indication ] On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Guangdong Hengrui Pharmaceutical had received an NMPA Clinical Trial Approval Notice for SHR-1179 injection, approving clinical trials for the weight management indication. The drug is a therapeutic Class 1 biological product independently developed by the company, with no drug targeting the same pathway yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 24.2 million.
Tag： HENGRUI PHARMA01276.HKClinical Trial
18:50
[ CHINA OVERSEAS (00688.HK): Proposed spin-off of Foshan Qiandeng Lake Unicenter project into public commercial REIT for independent listing on SZSE, application submitted by ChinaAMC and CITIC Securities ] On 7 September 2026, CHINA OVERSEAS (00688.HK) announced that China Asset Management and CITIC Securities had submitted application materials for the registration and listing of a public commercial REIT with the CSRC and the SZSE. The company proposes to spin off the Foshan Qiandeng Lake Unicenter shopping mall project into a public REIT for independent listing on the SZSE, with expected gross proceeds of approximately RMB 1.534 billion and a group subscription for approximately 20% of the issued fund units, after which the project company will be 100% held by the REIT and deconsolidated. As all applicable percentage ratios are below 5%, the proposed spin-off is not subject to the Chapter 14 reporting, announcement or shareholders' approval requirements, and the company has applied for a waiver from the assured entitlement requirement under paragraph 3(f) of Practice Note 15.
Tag： CHINA OVERSEAS00688.HKSpin-offREITs
18:41
[ LONGSYS (09976.HK): H-share offering priced at HKD 236, grey market closed at HKD 234.40, listing set for 8 September ] On 7 September 2026, LONGSYS (09976.HK) announced a final H-share offer price of HKD 236 per share, with the H shares expected to list on the Main Board of the Stock Exchange of Hong Kong on 8 September 2026. In the grey market on the same day, the H shares closed at HKD 234.40, a small discount of approximately 0.68% to the issue price.
Tag： 09976.HKLONGSYSGrey Market
18:20
[ CIFI HOLD GP (00884.HK): Contracted sales of about RMB 660 million in August 2026, cumulative about RMB 6.30 billion in the first eight months ] On 7 September 2026, CIFI HOLD GP (00884.HK) announced its unaudited operational data for August 2026, recording contracted sales (including contracted sales of joint ventures and associates) of approximately RMB 660 million with contracted sales area of approximately 62,400 sq.m. and an average contracted selling price of approximately RMB 11,700 per sq.m. in the month, and cumulative contracted sales of approximately RMB 6.30 billion with contracted sales area of approximately 649,800 sq.m. and shareholders' attributable contracted sales of approximately RMB 3.33 billion for January to August 2026.
Tag： CIFI HOLD GP00884.HKBusiness Data
18:18
[ AGILE GROUP (03383.HK): Pre-sales of about RMB 380 million in August 2026, cumulative about RMB 4.67 billion in the first eight months ] On 7 September 2026, AGILE GROUP (03383.HK) announced its unaudited operational data for August 2026, recording aggregate pre-sales of approximately RMB 380 million with a corresponding floor area of approximately 46,000 sq.m. at an average price of RMB 8,234 per sq.m. in the month, and cumulative pre-sales of approximately RMB 4.67 billion with a floor area of approximately 520,000 sq.m. at an average price of RMB 8,977 per sq.m. for the eight months ended 31 August 2026.
Tag： AGILE GROUP03383.HKBusiness Data
18:12
[ CIL GROUP (01719.HK): Wholly-owned subsidiary to contribute RMB 8 million to port and shipping development fund with total commitments of RMB 300 million ] On 7 September 2026, CIL GROUP (01719.HK) announced that its wholly-owned subsidiary had entered into a limited partnership agreement with Changjiang Venture Capital, Hubei Ganghang and Wuhan Ganghang to establish a port and shipping development fund with total capital commitments of RMB 300 million (approximately HKD 351 million), to which the subsidiary will contribute RMB 8 million, representing about 2.66%. As the counterparties are associates of controlling shareholder Hubei Port Group, the transaction constitutes a connected transaction; with the highest applicable percentage ratio exceeding 0.1% but below 5%, it is subject to reporting and announcement requirements but exempt from circular and independent shareholders' approval.
Tag： CIL GROUP01719.HKEstablish a fund
17:56
[ SHOUGANG LANZA (02553.HK): H shares included in Stock Connect eligible securities list effective 7 September ] On 7 September 2026, SHOUGANG LANZA (02553.HK) voluntarily announced that its H shares had been included in the eligible securities list of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect (collectively, Stock Connect), effective from the same day, enabling eligible mainland investors to buy and sell its H shares directly through the scheme, which is expected to broaden the company's investor base and may increase the trading liquidity of its H shares.
Tag： SHOUGANG LANZA02553.HKStock Connect
17:53
[ UNISOUND (09678.HK): Wins multiple benchmark medical projects with total contract value of nearly RMB 100 million ] On 7 September 2026, UNISOUND (09678.HK) voluntarily announced progress in its medical intelligence business, having recently won multiple benchmark smart healthcare projects, including large-model projects at leading Class 3A hospitals, an intelligent fund supervision project for a leading insurance institution and a regional medical intelligence construction project, with a combined contract value of nearly RMB 100 million. The projects are based on vertical large models trained on the company's proprietary foundational model U2, covering in-hospital diagnosis and treatment, fund supervision and regional data governance.
Tag： UNISOUND09678.HKwon the bid
17:50
[ HK Stock Connect Daily Report: HSI falls 0.93% as Stock Connect list adjustment takes effect, 54 stocks added and 15 removed - 20260907 ] On 7 September, Hong Kong's three major indices came under pressure: the Hang Seng Index fell 0.93% to close at 25,413.12 points and the Hang Seng TECH Index fell 0.92%, with turnover of HK$ 209.673 billion. The Stock Connect eligible list was formally adjusted today, with 54 securities added and 15 removed; Baidu was formally included in Stock Connect, and Citi expects about HK$ 47 billion of incremental inflows over the next 2 to 4 months. On the trading front, optical communication, PCB and other computing-power hardware chains led gains, with CIG up over 24% and ZJ INNOLIGHT up nearly 20%; Chinese banking H-shares broadly corrected and AI application and heavyweight technology stocks weakened. Southbound capital recorded net buying of HK$ 1.275 billion.
Tag： HK Stock Connect Daily ReportMANYCORE TECHMINIMAX-W
17:46
[ WISDOM WEALTH (00007.HK): HKEX announces cancellation of listing effective 9:00 a.m. on 9 September ] On 7 September 2026, The Stock Exchange of Hong Kong Limited announced that the listing status of WISDOM WEALTH (00007.HK) would be cancelled with effect from 9:00 a.m. on 9 September 2026 under Rule 6.01A(1) of the Listing Rules. The company's shares have been suspended since 2 April 2024, and it failed to resume trading on or before 1 October 2025, leading to two delisting decisions by the Listing Committee and an upholding review decision by the Listing Review Committee on 27 August 2026.
Tag： WISDOM WEALTH00007.HKDelisting
17:42
[ YUK WING GP (01536.HK): Executive director and CEO Hu Lanying resigns, Tsang Ka Yan appointed executive director ] On 7 September 2026, YUK WING GP (01536.HK) announced that Ms. Hu Lanying had resigned as executive director and chief executive officer to focus on other business development with effect from the same day, and that Miss Tsang Ka Yan (formerly known as Tsang Ka Yan) had been appointed as executive director, also with effect from 7 September 2026. Miss Tsang has entered into a one-year service agreement and is entitled to an annual director's fee of HKD 1,000,000, holding office until the first annual general meeting following her appointment.
Tag： YUK WING GP01536.HKresignation
Previous1..7273 747576..576     576 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments